Literature DB >> 11518797

Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor.

A García1, C V Alvarez, R G Smith, C Diéguez.   

Abstract

GH secretagogues are an expanding class of synthetic peptide and nonpeptide molecules that stimulate the pituitary gland to secrete GH through their own specific receptor, the GH-secretagogue receptor. The cloning of the receptor for these nonclassical GH releasing molecules, together with the more recent characterization of an endogenous ligand, named ghrelin, have unambiguously demonstrated the existence of a physiological system that regulates GH secretion. Somatotroph cell-specific expression of the GH gene is dependent on a pituitary-specific transcription factor (Pit-1). This factor is transcribed in a highly restricted manner in the anterior pituitary gland. The present experiments sought to determine whether the synthetic hexapeptide GHRP-6, a reference GH secretagogue compound, as well as an endogenous ligand, ghrelin, regulate pit-1 expression. By a combination of Northern and Western blot analysis we found that GHRP-6 elicits a time- and dose-dependent activation of pit-1 expression in monolayer cultures of infant rat anterior pituitary cells. This effect was blocked by pretreatment with actinomycin D, but not by cycloheximide, suggesting that this action was due to direct transcriptional activation of pit-1. Using an established cell line (HEK293-GHS-R) that overexpresses the GH secretagogue receptor, we showed a marked stimulatory effect of GHRP-6 on the pit-1 -2,500 bp 5'-region driving luciferase expression. We truncated the responsive region to -231 bp, a sequence that contains two CREs, and found that both CREs are needed for GHRP-6-induced transcriptional activation in both HEK293-GHS-R cells and infant rat anterior pituitary primary cultures. The effect was dependent on PKC, MAPK kinase, and PKA activation. Increasing Pit-1 by coexpression of pCMV-pit-1 potentiated the GHRP-6 effect on the pit-1 promoter. Similarly, we showed that the endogenous GH secretagogue receptor ligand ghrelin exerts a similar effect on the pit-1 promoter. These data provide the first evidence that ghrelin, in addition to its previously reported GH-releasing activities, is also capable of regulating pit-1 transcription through the GH secretagogue receptor in the pituitary, thus giving new insights into the physiological role of the GH secretagogue receptor on somatotroph cell differentiation and function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518797     DOI: 10.1210/mend.15.9.0694

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  18 in total

Review 1.  Leptin and ghrelin: what is the impact on pituitary function?

Authors:  Felipe F Casanueva; Carlos Dieguez
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

2.  Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway.

Authors:  Delphine Mousseaux; Lionel Le Gallic; Joanne Ryan; Catherine Oiry; Didier Gagne; Jean-Alain Fehrentz; Jean-Claude Galleyrand; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

3.  The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth.

Authors:  Carmen Cañibano; Noela L Rodriguez; Carmen Saez; Sulay Tovar; Montse Garcia-Lavandeira; Maria Grazia Borrello; Anxo Vidal; Frank Costantini; Miguel Japon; Carlos Dieguez; Clara V Alvarez
Journal:  EMBO J       Date:  2007-03-22       Impact factor: 11.598

Review 4.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

5.  Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature.

Authors:  Jacques Pantel; Marie Legendre; Sylvie Cabrol; Latifa Hilal; Yassir Hajaji; Séverine Morisset; Sylvie Nivot; Marie-Pierre Vie-Luton; Dominique Grouselle; Marc de Kerdanet; Abdelkrim Kadiri; Jacques Epelbaum; Yves Le Bouc; Serge Amselem
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

6.  Pendred syndrome in two Galician families: insights into clinical phenotypes through cellular, genetic, and molecular studies.

Authors:  Fernando Palos; María E R García-Rendueles; David Araujo-Vilar; Maria Jesús Obregon; Rosa Maria Calvo; Jose Cameselle-Teijeiro; Susana B Bravo; Oscar Perez-Guerra; Lourdes Loidi; Barbara Czarnocka; Paula Alvarez; Samuel Refetoff; Lourdes Dominguez-Gerpe; Clara V Alvarez; Joaquin Lado-Abeal
Journal:  J Clin Endocrinol Metab       Date:  2007-10-16       Impact factor: 5.958

7.  Reduction in hypophyseal growth hormone and prolactin expression due to deficiency in ghrelin receptor signaling is associated with Pit-1 suppression: relevance to the immune system.

Authors:  Hyunwon Yang; Vishwa D Dixit; Kalpesh Patel; Bolormaa Vandanmagsar; Gary Collins; Yuxiang Sun; Roy G Smith; Dennis D Taub
Journal:  Brain Behav Immun       Date:  2008-06-17       Impact factor: 7.217

Review 8.  Ghrelin in neuroendocrine organs and tumours.

Authors:  Chrysanthia A Leontiou; Giulia Franchi; Márta Korbonits
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

9.  Sex differences in somatotrope response to fasting: biphasic responses in male mice.

Authors:  Tiffany K Miles; Ana Rita Silva Moreira; Melody L Allensworth-James; Angela K Odle; Anessa C Haney; Angus M MacNicol; Melanie C MacNicol; Gwen V Childs
Journal:  J Endocrinol       Date:  2020-12       Impact factor: 4.286

Review 10.  The cellular and molecular bases of leptin and ghrelin resistance in obesity.

Authors:  Huxing Cui; Miguel López; Kamal Rahmouni
Journal:  Nat Rev Endocrinol       Date:  2017-02-24       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.